Opinion
Video
Innovations Needed and Future Directions in Treatment of NSCLC
Concluding thoughts on data presented at ESMO 2023, and innovations still needed for improved survival of NSCLC—provided by Patrick Forde, MBBCh.
This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.
Forde summarizes that significant advances have been made in non–small cell lung cancer (NSCLC), especially in the first-line setting for advanced disease and increasingly for early-stage disease with neoadjuvant immunotherapy. He notes further work is needed to improve outcomes for early-stage patients without a pathologic complete response to neoadjuvant therapy. Additional adjuvant targeted therapy trials are warranted in oncogene-driven NSCLC subtypes beyond EGFR and ALK.
In advanced NSCLC, numerous first-line options now exist, but second-line options remain very limited following first-line chemoimmunotherapy. Forde discusses the inconclusive TROPION-LUNG01 (NCT04656652) study in a novel postchemoimmunotherapy second-line setting. Clearly more work is needed in the second-line advanced setting.
In first-line EGFR-mutant advanced NSCLC, Forde notes the MARIPOSA trial (NCT04487080) showed improved progression-free survival with amivantamab-nazartinib vs osimertinib, but toxicity was increased, so more data are needed before practice changes. In contrast, the second-line MARIPOSA-2 trial (NCT04988295) supports adding amivantamab to chemotherapy vs chemotherapy alone post osimertinib, given the HR of 0.44 favoring the combination. However, toxicity requires monitoring with amivantamab-containing regimens.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
